A detailed history of Price T Rowe Associates Inc transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 31,431 shares of STOK stock, worth $398,230. This represents 0.0% of its overall portfolio holdings.

Number of Shares
31,431
Previous 29,789 5.51%
Holding current value
$398,230
Previous $157,000 170.7%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$4.12 - $14.17 $6,765 - $23,267
1,642 Added 5.51%
31,431 $425,000
Q3 2023

Nov 14, 2023

SELL
$3.78 - $11.99 $1.24 Million - $3.95 Million
-329,133 Reduced 91.7%
29,789 $118,000
Q2 2023

Aug 14, 2023

SELL
$7.93 - $13.82 $149,710 - $260,907
-18,879 Reduced 5.0%
358,922 $3.82 Million
Q1 2023

May 15, 2023

SELL
$7.65 - $10.38 $132,390 - $179,636
-17,306 Reduced 4.38%
377,801 $3.15 Million
Q4 2022

Feb 14, 2023

SELL
$7.07 - $15.69 $121,858 - $270,432
-17,236 Reduced 4.18%
395,107 $3.65 Million
Q3 2022

Nov 14, 2022

SELL
$12.56 - $22.53 $54,987 - $98,636
-4,378 Reduced 1.05%
412,343 $5.3 Million
Q2 2022

Aug 15, 2022

SELL
$10.36 - $23.93 $73,991 - $170,908
-7,142 Reduced 1.68%
416,721 $5.51 Million
Q1 2022

May 16, 2022

SELL
$17.19 - $26.1 $247,260 - $375,422
-14,384 Reduced 3.28%
423,863 $8.92 Million
Q4 2021

Feb 14, 2022

BUY
$18.11 - $30.72 $1.82 Million - $3.09 Million
100,665 Added 29.82%
438,247 $10.5 Million
Q3 2021

Nov 15, 2021

SELL
$23.65 - $34.44 $1.18 Million - $1.72 Million
-49,841 Reduced 12.86%
337,582 $8.59 Million
Q2 2021

Aug 16, 2021

SELL
$30.53 - $41.09 $7.2 Million - $9.69 Million
-235,769 Reduced 37.83%
387,423 $13 Million
Q1 2021

May 17, 2021

SELL
$36.08 - $69.81 $4.56 Million - $8.83 Million
-126,434 Reduced 16.87%
623,192 $24.2 Million
Q4 2020

Feb 16, 2021

BUY
$33.62 - $61.93 $25.2 Million - $46.4 Million
749,626 New
749,626 $46.4 Million

Others Institutions Holding STOK

About Stoke Therapeutics, Inc.


  • Ticker STOK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,419,300
  • Market Cap $499M
  • Description
  • Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...
More about STOK
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.